Logo

Sun Pharma Reports Four Years Result of Ilumya (tildrakizumab-asmn) in P-III reSURFACE 1 and 2 Trials in Patients with Moderate-to-Severe Plaque Psoriasis

Share this

Sun Pharma Reports Four Years Result of Ilumya (tildrakizumab-asmn) in P-III reSURFACE 1 and 2 Trials in Patients with Moderate-to-Severe Plaque Psoriasis

Shots:

  • The P-III reSURFACE 1 and 2 are extension-study involves assessing of Ilumya (100 &200 mg at 0 and 4wks.) and Ilumya (100 & 200 mg) vs PBO and etanercept (50 mg) respectively. The reSURFACE 1 and reSURFACE 2 Post-Hoc Analyses was conducted to evaluate changes in efficacy of Ilumya in patients with/out metabolic syndrome  
  • P-III reSURFACE 1 & 2 extension study@ 100mg: PASI 75/90/100 (82%/56%/28% & 89%/64%/35%) and % of PGA response: (58% & 65%). Post-Hoc Analysis @100mg reSURFACE 1 & 2 with/out metabolic syndrome: PASI 75 (69%/71% & 73%/79%)- PASI 90 (42%/51% & 57%/60%)- PASI 100 (27%/23% & 34%/32%) respectively; Presented at EADV 2019
  • Ilumya is an lgG1/k mAb binds with p19 subunit of IL-23 while inhibiting its interaction with the IL-23 receptor further leading inhibition of the release of pro-inflammatory cytokines and chemokines and is approved for mod-to-sev plaque psoriasis in Australia and EU with brand name Ilumetri 

Click here to­ read full press release/ article | Ref: Sun Pharma | Image: PharmaWorld


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions